Antipsychotic medication and prefrontal cortex activation: A review of neuroimaging findings

@article{Liemburg2012AntipsychoticMA,
  title={Antipsychotic medication and prefrontal cortex activation: A review of neuroimaging findings},
  author={E. Liemburg and H. Knegtering and H. Klein and R. Kortekaas and A. Aleman},
  journal={European Neuropsychopharmacology},
  year={2012},
  volume={22},
  pages={387-400}
}
Decreased prefrontal activation (hypofrontality) in schizophrenia is thought to underlie negative symptoms and cognitive impairments, and may contribute to poor social outcome. Hypofrontality does not always improve during treatment with antipsychotics. We hypothesized that antipsychotics, which share antagonism at dopamine receptors, with a relatively low dopamine receptor affinity and high serotonin receptor affinity may have a sparing effect on prefrontal function compared to strong dopamine… Expand
Reviewing the ketamine model for schizophrenia
...
1
2
3
4
...

References

SHOWING 1-10 OF 114 REFERENCES
Prefrontal function in schizophrenia: confounds and controversies.
  • D. Weinberger, K. Berman
  • Biology, Medicine
  • Philosophical transactions of the Royal Society of London. Series B, Biological sciences
  • 1996
Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia.
Beyond hypofrontality: A quantitative meta‐analysis of functional neuroimaging studies of working memory in schizophrenia
Anatomical and functional brain variables associated with clozapine response in treatment-resistant schizophrenia
Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia
Failure to deactivate in the prefrontal cortex in schizophrenia: dysfunction of the default mode network?
...
1
2
3
4
5
...